AstraZeneca (LON:AZN) Earns “Hold” Rating from Deutsche Bank Aktiengesellschaft

AstraZeneca (LON:AZN)‘s stock had its “hold” rating restated by stock analysts at Deutsche Bank Aktiengesellschaft in a research note issued to investors on Tuesday, September 29th, Digital Look reports. They presently have a £117 target price on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s target price indicates a potential downside of 2.16% from the company’s current price.

AZN has been the subject of several other reports. Jefferies Financial Group restated a “buy” rating and issued a £175 target price on shares of AstraZeneca in a research note on Wednesday, September 9th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a £145 price target on shares of AstraZeneca in a research note on Tuesday, September 8th. Citigroup increased their price target on AstraZeneca from £175 to £178 and gave the stock a “buy” rating in a report on Tuesday, July 28th. Finally, Berenberg Bank reduced their price objective on AstraZeneca from £160 to £150 and set a “buy” rating for the company in a research note on Tuesday, September 15th. Six research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, AstraZeneca presently has an average rating of “Moderate Buy” and an average target price of £150.

AstraZeneca Stock Up 1.6%

AZN traded up GBX 194 during midday trading on Tuesday, hitting £119.58. The company had a trading volume of 2,155,023 shares, compared to its average volume of 29,557,594. The stock’s 50 day moving average price is £121.13 and its 200 day moving average price is £132.49. AstraZeneca has a 52 week low of £114.04 and a 52 week high of £157.32. The company has a market capitalization of £185.46 billion, a price-to-earnings ratio of 17.90, a PEG ratio of 0.86 and a beta of 0.20. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 64.10.

Insider Transactions at AstraZeneca

In other news, insider Michel Demare acquired 2,500 shares of the business’s stock in a transaction on Monday, September 14th. The shares were purchased at an average cost of £121.21 per share, with a total value of £303,025. Company insiders own 0.15% of the company’s stock.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.